Welcome to the UPF Digital Repository

Optimized dual-time-window protocols for quantitative [18F]flutemetamol and [18F]florbetaben PET studies

Show simple item record

dc.contributor.author Heeman, Fiona
dc.contributor.author Yaqub, Maqsood
dc.contributor.author Lopes Alves, Isadora
dc.contributor.author Heurling, Kerstin
dc.contributor.author Berkhof, Johannes
dc.contributor.author Gispert López, Juan Domingo
dc.contributor.author Bullich, Santiago
dc.contributor.author Foley, Christopher
dc.contributor.author Lammertsma, Adriaan A.
dc.contributor.author AMYPAD Consortium
dc.date.accessioned 2020-07-22T06:39:08Z
dc.date.available 2020-07-22T06:39:08Z
dc.date.issued 2019
dc.identifier.citation Heeman F, Yaqub M, Lopes Alves I, Heurling K, Berkhof J, Gispert JD, Bullich S, Foley C, Lammertsma AA; AMYPAD Consortium. Optimized dual-time-window protocols for quantitative [18F]flutemetamol and [18F]florbetaben PET studies. EJNMMI Res. 2019; 9(1):32. DOI: 10.1186/s13550-019-0499-4
dc.identifier.issn 2191-219X
dc.identifier.uri http://hdl.handle.net/10230/45152
dc.description.abstract Background: A long dynamic scanning protocol may be required to accurately measure longitudinal changes in amyloid load. However, such a protocol results in a lower patient comfort and scanning efficiency compared to static scans. A compromise can be achieved by implementing dual-time-window protocols. This study aimed to optimize these protocols for quantitative [18F]flutemetamol and [18F]florbetaben studies. Methods: Rate constants for subjects across the Alzheimer's disease spectrum (i.e., non-displaceable binding potential (BPND) in the range 0.02-0.77 and 0.02-1.04 for [18F]flutemetamol and [18F]florbetaben, respectively) were established based on clinical [18F]flutemetamol (N = 6) and [18F]florbetaben (N = 20) data, and used to simulate tissue time-activity curves (TACs) of 110 min using a reference tissue and plasma input model. Next, noise was added (N = 50) and data points corresponding to different intervals were removed from the TACs, ranging from 0 (i.e., 90-90 = full-kinetic curve) to 80 (i.e., 10-90) minutes, creating a dual-time-window. Resulting TACs were fitted using the simplified reference tissue method (SRTM) to estimate the BPND, outliers (≥ 1.5 × BPND max) were removed and the bias was assessed using the distribution volume ratio (DVR = BPND + 1). To this end, acceptability curves, which display the fraction of data below a certain bias threshold, were generated and the area under those curves were calculated. Results: [18F]Flutemetamol and [18F]florbetaben data demonstrated an increased bias in amyloid estimate for larger intervals and higher noise levels. An acceptable bias (≤ 3.1%) in DVR could be obtained with all except the 10-90 and 20-90-min intervals. Furthermore, a reduced fraction of acceptable data and most outliers were present for these two largest intervals (maximum percentage outliers 48 and 32 for [18F]flutemetamol and [18F]florbetaben, respectively). Conclusions: The length of the interval inversely correlates with the accuracy of the BPND estimates. Consequently, a dual-time-window protocol of 0-30 and 90-110 min (=maximum of 60 min interval) allows for accurate estimation of BPND values for both tracers. [18F]flutemetamol: EudraCT 2007-000784-19, registered 8 February 2007, [18F]florbetaben: EudraCT 2006-003882-15, registered 2006.
dc.format.mimetype application/pdf
dc.language.iso eng
dc.publisher Springer
dc.relation.ispartof EJNMMI Res. 2019; 9(1):32
dc.rights © The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
dc.rights.uri http://creativecommons.org/licenses/by/4.0/
dc.title Optimized dual-time-window protocols for quantitative [18F]flutemetamol and [18F]florbetaben PET studies
dc.type info:eu-repo/semantics/article
dc.identifier.doi http://dx.doi.org/10.1186/s13550-019-0499-4
dc.subject.keyword Alzheimer’s disease
dc.subject.keyword Amyloid
dc.subject.keyword Florbetaben PET
dc.subject.keyword Flutemetamol PET
dc.subject.keyword Quantification
dc.subject.keyword Simplified methods
dc.relation.projectID info:eu-repo/grantAgreement/EC/H2020/115952
dc.rights.accessRights info:eu-repo/semantics/openAccess
dc.type.version info:eu-repo/semantics/publishedVersion

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Search DSpace


Advanced Search

Browse

My Account

Statistics

In collaboration with Compliant to Partaking